埃克替尼治疗表皮生长因子受体敏感突变的晚期非小细胞肺癌获益患者的临床分析(1)
[摘要]目的 探讨埃克替尼治疗表皮生长因子受体(EGFR)敏感突变的晚期非小细胞肺癌获益患者的临床效果。方法 选取2013年1月～2014年12月来我院治疗的68例EGFR敏感突变的晚期非小细胞肺癌获益患者，采用单双号随机分为甲乙两组，每组34例。给予甲组患者埃克替尼治疗，给予乙组患者吉非替尼治疗，对比观察两组患者总有效率、获益率、体力状况评分及不良反应发生情况。结果 甲组患者总有效率为82.4%，乙组为76.5%，差异有统计学意义(P<0.05)；甲组1年获益率及体力状况评分略优于乙组，2年获益率两组相当，差异无统计学意义(P>0.05)；甲组患者不良反应发生率低于乙组(P<0.05)。结论 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌患者效果显著，且不良反应小，值得临床推广。
[关键词]埃克替尼；EGFR敏感突变；晚期非小细胞肺癌
[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721(2016)10(c)-0059-03
[Abstract]Objective To explore clinical effect of Icotinib in treatment of epidermal growth factor receptor (EGFR) sensitive mutations in patients with advanced non-small cell lung cancer benefit.Methods 68 patients of EGFR sensitive mutations with advanced non-small cell lung cancer benefit in our hospital from January 2013 to December 2014 were selected and randomly divided into two groups by using single and double number ......
您现在查看是摘要页，全文长 3395 字符。
[关键词]埃克替尼；EGFR敏感突变；晚期非小细胞肺癌
[中图分类号] R734.2 [文献标识码] A [文章编号] 1674-4721(2016)10(c)-0059-03
[Abstract]Objective To explore clinical effect of Icotinib in treatment of epidermal growth factor receptor (EGFR) sensitive mutations in patients with advanced non-small cell lung cancer benefit.Methods 68 patients of EGFR sensitive mutations with advanced non-small cell lung cancer benefit in our hospital from January 2013 to December 2014 were selected and randomly divided into two groups by using single and double number ......
您现在查看是摘要页，全文长 3395 字符。